Samsung Pharm Asset Resilience Ratio

Latest as of September 2025: 6.69%

Samsung Pharm asset resilience ratio. Samsung Pharm (001360) has an Asset Resilience Ratio of 6.69% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Samsung Pharm defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩15.00 Billion
≈ $10.17 Million USD Cash + Short-term Investments

Total Assets

₩224.14 Billion
≈ $151.89 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Samsung Pharm (2015–2024)

Asset resilience ratio of Samsung Pharm from 2015 to 2024. This chart shows how Samsung Pharm's Asset Resilience Ratio has changed over time. Read Samsung Pharm total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Samsung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Samsung Pharm's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩15.00 Billion 6.69%
Total Liquid Assets ₩15.00 Billion 6.69%

Asset Resilience Insights

  • Limited Liquidity: Samsung Pharm maintains only 6.69% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Samsung Pharm Industry Peers by Asset Resilience Ratio

Compare Samsung Pharm's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Galderma Group N
SW:GALD
Drug Manufacturers - Specialty & Generic 3.56%
Enzymatica publ AB
ST:ENZY
Drug Manufacturers - Specialty & Generic 22.17%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 9.04%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%

Samsung Pharm Asset Resilience Ratio by Year (2015–2024)

Samsung Pharm asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Samsung Pharm.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.34% ₩3.00 Billion
≈ $2.03 Million
₩128.45 Billion
≈ $87.05 Million
-14.63pp
2022-12-31 16.96% ₩20.00 Billion
≈ $13.55 Million
₩117.91 Billion
≈ $79.91 Million
-9.37pp
2021-12-31 26.33% ₩38.30 Billion
≈ $25.96 Million
₩145.46 Billion
≈ $98.57 Million
+24.89pp
2020-12-31 1.45% ₩2.59 Billion
≈ $1.75 Million
₩178.73 Billion
≈ $121.12 Million
-14.58pp
2019-12-31 16.03% ₩27.02 Billion
≈ $18.31 Million
₩168.53 Billion
≈ $114.21 Million
-10.47pp
2018-12-31 26.50% ₩42.57 Billion
≈ $28.85 Million
₩160.65 Billion
≈ $108.87 Million
+8.42pp
2017-12-31 18.08% ₩27.88 Billion
≈ $18.89 Million
₩154.19 Billion
≈ $104.50 Million
+13.01pp
2016-12-31 5.08% ₩7.02 Billion
≈ $4.76 Million
₩138.28 Billion
≈ $93.71 Million
-4.91pp
2015-12-31 9.99% ₩13.01 Billion
≈ $8.81 Million
₩130.22 Billion
≈ $88.25 Million
--
pp = percentage points

About Samsung Pharm

KO:001360 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$76.73 Million
₩113.23 Billion KRW
Market Cap Rank
#20048 Global
#1060 in Korea
Share Price
₩1203.00
Change (1 day)
-2.20%
52-Week Range
₩1180.00 - ₩2210.00
All Time High
₩12289.83
About

SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamin… Read more